Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Development of a European… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report.

Artikel i vetenskaplig tidskrift
Författare A Cull
S Howat
E Greimel
Ann-Charlotte Waldenström
J Arraras
A Kudelka
L Chauvenet
A Gould
EORTC Qual of life Group
Scott Gyn Cancer Trial Group
Publicerad i European journal of cancer (Oxford, England : 1990)
Volym 37
Nummer/häfte 1
Sidor 47-53
ISSN 0959-8049
Publiceringsår 2001
Publicerad vid Institutionen för särskilda specialiteter, Avdelningen för onkologi
Sidor 47-53
Språk en
Länkar www.ncbi.nlm.nih.gov/entrez/query.f...
Ämnesord Antineoplastic Agents, adverse effects, Clinical Trials, Female, Humans, Middle Aged, Ovarian Neoplasms, drug therapy, Quality of Life, Questionnaires, standards
Ämneskategorier Cancer och onkologi

Sammanfattning

A questionnaire was developed, according to the European Organization for Research and Treatment of Cancer (EORTC) published guidelines, to supplement the EORTC quality of life questionnaire-core 30 (QLQ-C30) to assess the quality of life (QL) of women with ovarian cancer treated in clinical trials. The provisional 28-item module, OV28, assesses abdominal symptoms; peripheral neuropathy; other chemotherapy side-effects; hormonal symptoms; body image; attitude to disease and treatment; and sexual functioning. The first 24 items of the module (excluding sexual functioning) were included in a UK multicentre trial (SCOTROC). The trial data were used for preliminary scaling analysis. Two problematic items were identified. When these were treated as single items along with the 'other chemotherapy side-effects' the instrument showed excellent scale properties. Mean scale scores discriminated between trial patients pre- and on chemotherapy. This is a promising tool for assessing the QL of women with ovarian cancer. The EORTC international field study (Protocol 15982) to assess more fully the psychometric properties of the OV28 is well underway.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?